Skip to main content
GlaxoSmithkline Pharmaceuticals Ltd. logo

GlaxoSmithkline Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · GLAXO ISIN · INE159A01016 LEI · 3358002TNSC1U2DWNY52 BSE.NS Manufacturing
Open in API
Filings indexed 1,605 across all filing types
Latest filing 2026-02-16 Call Transcript
Country IN India
Listing BSE.NS GLAXO

About GlaxoSmithkline Pharmaceuticals Ltd.

https://india-pharma.gsk.com/en-in/home/

GlaxoSmithkline Pharmaceuticals Ltd. is a research-based organization specializing in the development, manufacture, and commercialization of prescription medicines and vaccines. The company’s portfolio spans multiple therapeutic areas, including anti-infectives, dermatology, gynecology, oncology, and respiratory health. Key products include Augmentin, Calpol, Ceftum, and Eltroxin. It maintains a significant presence in the vaccines sector, offering protection against diseases such as pneumococcal infection, hepatitis, and varicella. By integrating global research and development expertise, the entity focuses on delivering innovative treatments and improving patient outcomes. Its operations are supported by a robust supply chain and distribution infrastructure designed to provide broad access to essential medical products.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of a Q3 FY 2026 earnings conference call for GlaxoSmithKline Pharmaceuticals Limited. It includes detailed management commentary on financial performance, business segments, growth drivers, and a Q&A session with analysts. The presence of management discussion, financial metrics like EBITDA, PAT, EPS, and detailed operational updates confirms this is a full transcript of an earnings call. The document is about 15,000 characters long, indicating it is a substantive transcript rather than a brief announcement or summary. Therefore, the document fits the category of a Call Transcript (CT).
2026-02-16 English
Transcript
Call Transcript Classification · 100% confidence The document is a transcript of a Q3 FY 2026 earnings conference call for GlaxoSmithKline Pharmaceuticals Limited. It includes detailed management commentary on financial performance, business segments, growth drivers, and a Q&A session with analysts. The presence of management discussion, financial metrics like EBITDA, PAT, EPS growth, and detailed operational updates confirms this is a full transcript of an earnings call rather than a brief earnings release or a presentation. The document length (15,000 characters) and content depth support classification as a Call Transcript (CT).
2026-02-16 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges reporting the outcome of analyst and institutional investor meetings. It references compliance with SEBI regulations and provides a link to a video recording of the meetings. The content is brief (1249 characters) and does not contain any financial statements, detailed financial data, or comprehensive report content. It is an announcement about the schedule and outcome of meetings rather than the meetings' detailed transcripts or reports. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2026-02-11 English
As per attachment
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges reporting the outcome of analyst and institutional investor meetings. It references compliance with SEBI regulations and provides a link to a video recording of the meetings. The document is short (1249 characters) and does not contain any financial data, detailed financial results, or substantive analysis. It is an announcement about the schedule and outcome of investor meetings rather than a full investor presentation or financial report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-02-11 English
Copy of Newspaper Publication
Regulatory Filings
2026-02-10 English
As per attachment
Regulatory Filings
2026-02-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.